Xeris Biopharma Holdings Inc Receivables Turnover Ratio (XERS), from the second quarter 2026 to the second quarter 2025 current and historic results, rankings and more - CSIMarket
CSIMarket
 


Xeris Biopharma Holdings Inc   (NASDAQ: XERS)
 

Xeris Biopharma Holdings Inc Accounts Receivables Turnover Ratio from the second quarter 2026 to the second quarter 2025

Quarterly Results, Trends, Rankings, Statistics


Xeris Biopharma Holdings Inc 's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the second quarter 2026 to a ratio of 6.12, above the company average. This is a clear sign of healthy business climate in the Major Pharmaceutical Preparations industry and improving liquidity at their respective customers, during the second quarter 2026. Average receivable collection period, for the Xeris Biopharma Holdings Inc in Jun 30 2026 quarter, has decreased to 60 days, compared to 62 days, in the Mar 31 2026 quarter.

If we take a look into Healthcare sector 152 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Jun 30 2026 from 1171 to 1220.

What is Receivable Turnover Ratio?
What is Xeris Biopharma Holdings Inc Selling?


What is Receivable Turnover Ratio?





XERS Receivables Turnover Ratio (Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
Y / Y Receivable Change 9.53 % 21.51 % 26.31 % 30.66 % 25 %
Y / Y Revenue Change 28.74 % 38.27 % 42.78 % 37.06 % 48.84 %
Receivable Turnover Ratio (TTM) 6.12 5.88 5.72 5.5 5.44
XERS's Total Ranking # 1220 # 1171 # 1376 # 1084 # 1097
Accounts Receivable average collection period days 60 62 64 66 67
Seq. Receivable Change 3.22 % 10.27 % -5.03 % 1.33 % 14.5 %
Seq. Revenue Change 10.79 % -3.12 % 15.36 % 3.97 % 19 %


Receivable Turnover Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 38
Healthcare Sector # 153
Overall Market # 1220

Receivable Turnover Ratio Statistics
High Average Low
0.86 0.4 0
(Jun 30 2026)   (Sep 30 2019)






Financial Statements
Xeris Biopharma Holdings Inc 's Accounts Receivable $ 58 Millions Visit XERS's Balance sheet
Xeris Biopharma Holdings Inc 's Sales TTM $ 335 Millions Visit XERS's Income Statement
Sources of XERS's Revenues Visit XERS's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
XERS's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
XERS's Growth Rates XERS's Roa XERS's Inventory Turnover Ratio XERS's Dividend Comparisons
XERS's Profitability Ratios XERS's Roi XERS's Asset Turnover Ratio XERS's Dividend Growth
XERS's Valuation Ratios XERS's Roe XERS's Financial Strength Ratios XERS's Dividend Payout Ratio



Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector Receivable Turnover Ratio Revenues for 12 Months ending Jun 30 2026 Receivable at quarter ending Jun 30 2026
Neuraxis Inc   15.53 $ 5.316  Millions$ 0.342  Millions
Agenus Inc  15.44 $ 132.693  Millions$ 8.595  Millions
Longeveron Inc   15.03 $ 1.187  Millions$ 0.079  Millions
Medicinova Inc   15.02 $ 0.920  Millions$ 0.061  Millions
Voyager Therapeutics Inc   14.71 $ 34.459  Millions$ 2.343  Millions
Halozyme Therapeutics Inc   14.68 $ 1,663.738  Millions$ 113.332  Millions
Dar Bioscience Inc   14.57 $ 1.345  Millions$ 0.092  Millions
Nexgel Inc   14.52 $ 11.810  Millions$ 0.813  Millions
China Pharma Holdings Inc  14.46 $ 3.914  Millions$ 0.271  Millions
Lftd Partners Inc   14.13 $ 35.335  Millions$ 2.500  Millions
Talkspace Inc   14.09 $ 246.631  Millions$ 17.506  Millions
Lifestance Health Group Inc   14.07 $ 1,584.834  Millions$ 112.665  Millions
Ataibeckley Inc   13.83 $ 4.473  Millions$ 0.324  Millions
Amneal Pharmaceuticals Inc   13.83 $ 3,117.474  Millions$ 225.492  Millions
Arvinas Inc   13.49 $ 316.700  Millions$ 23.475  Millions
Rosecliff Acquisition Corp I  13.43 $ 16.467  Millions$ 1.226  Millions
Corcept Therapeutics Inc  13.30 $ 830.813  Millions$ 62.477  Millions
Precipio inc   13.25 $ 27.198  Millions$ 2.052  Millions
Skinhealth Systems Inc   13.04 $ 289.224  Millions$ 22.179  Millions
Chemed Corporation  12.94 $ 2,595.001  Millions$ 200.565  Millions
Qhslab Inc   12.77 $ 3.017  Millions$ 0.236  Millions
Mannkind Corporation  12.39 $ 393.630  Millions$ 31.773  Millions
Petvivo Holdings Inc   12.34 $ 1.182  Millions$ 0.096  Millions
Siga Technologies Inc  12.32 $ 53.659  Millions$ 4.356  Millions
Alpha Pro Tech Ltd   12.25 $ 62.204  Millions$ 5.077  Millions
Vivos Therapeutics Inc   12.21 $ 21.135  Millions$ 1.731  Millions
Milestone Scientific Inc   11.82 $ 8.855  Millions$ 0.749  Millions
Marpai Inc  11.71 $ 16.635  Millions$ 1.420  Millions
Catheter Precision Inc   11.62 $ 1.915  Millions$ 0.165  Millions
Icu Medical Inc  11.42 $ 2,159.998  Millions$ 189.166  Millions

Date modified: 2026-09-05T15:41:01+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.